A new study published in the journal of BMC Gastroenterology showed that dementia risk was higher in patients with metabolic ...

Researchers at the University of Oklahoma report a hormone, FGF21, may reverse fatty liver disease by signaling the brain.

A pioneering research study published today in Cell Metabolism details how the hormone FGF21 (fibroblast growth factor 21) ...

A new blood test can predict the development of metabolic dysfunction-associated steatotic liver disease (MASLD) up to 16 ...

Aroosha Sarrafi tells Health her story of getting diagnosed with metabolic dysfunction-associated steatohepatitis (MASH), a ...

Pregnant women with MASLD have over three times the risk of preterm birth, according to Swedish registry data. This risk ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial ...

Women who experience menopause before the age of 50 - and especially before the age of 45 - are more likely to develop fatty liver disease and its related metabolic risk factors within one year after ...

Pregnant women with metabolic dysfunction-associated steatotic liver disease (MASLD) have an increased risk of giving birth prematurely and the risk increase cannot be explained by obesity, according ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Bariatric surgery and GLP-1s conferred similar outcomes in mortality, adverse cardiovascular events and cirrhosis development ...

DelveInsight's analysis forecasts liver fibrosis market growth due to the introduction of emerging therapies, expecting an increase in market size during the study period (2020–2034). This anticipated ...